A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. 2. Juni 2013 Kasper, S., Overkamp, F., Moehler, M., Kullmann, F., Lang, H., Schoen, M., Smith-Machnow, V., Hegewisch-Becker, S., Seehofer, D., Bechstein, W., Heike, M., Voehringer, M., Heinemann, V., Greil, R., Geissler, M., Lordick, F., Peeters, M., Van Cutsem, E., Galle, P.R., Schimanski, C.C., 2013. J Clin Oncol 31(suppl; abstr TPS3124). doi: 10.1200/jco.2013.31.15_suppl.tps3124 Abstract Prediction of second-line therapy response in metastatic renal cell carcinoma patients by blood plasma marker proteins. Hölters, S., Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Staehler, M., Schmerler, D., Junker, K., 2013. Meeting of the EAU Section of Urological Research… Weiterlesen VMP in 1st-Line Treatment of Non-Transplant Patients with Multiple Myeloma in Routine Practice: First Follow-Up Data from the Tumour Registry Lymphatic Neoplasms. Knauf, W., Abenhardt, W., Harich, H.-D., Schlag, R., Grugel, R., Marschner, N., 2013. Onkologie 36 (suppl 7)(P528), 152–153. doi:10.1159/000356365 Abstract… Weiterlesen